Core Decompression Versus Core Decompression With Platelet-Rich Plasma Instillation for Treatment of Early Stage Avascular Necrosis of Femoral Head

November 2, 2026 updated by: Ain Shams University

This study aims to compare core decompression, a classic technique used for the treatment of avascular necrosis of the femoral head, versus core decompression augmented with PRP instillation, and how it affects the outcome of the disease.

Study Overview

Detailed Description

A total of 30 hips with stage 1 or 2 avascular necrosis of the femoral head according to the Arlet and Ficat classification were included in the study. Using randomized allocation, 15 hips underwent core decompression alone and 15 hips underwent core decompression with Platelet-Rich-Plasma instillation.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Cairo Governorate
      • Abbassia, Cairo Governorate, Egypt, 00202
        • Faculty of Medicine - Ain Shams University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Males and females.
  • Age greater-than 18 years old.
  • Patients diagnosed with unilateral or bilateral avascular necrosis of the femoral head presenting in the pre-collapse phase, Arlet and Ficat stage I and II.
  • Patients who agree to participate in the study and signed an informed consent.

Exclusion Criteria:

  • AVNFH with Arlet and Ficat stage III, and IV
  • Patients not willing to participate or refused to sign an informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Core Decompression

This is the classic gold standard technique used for these types of patients

The classic technique used to manage these types of cases

Experimental: Core Decompression with PRP Instillation

This is an augmented form of core decompression which includes a biological enhancement by adding PRP instillation

The classic technique used to manage these types of cases

Augmenting Core Decompression with PRP instillation as a biological enhancement to a classic technique

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Harris Hip Score
Time Frame: 18 months post intervention

A numerical assessment measurement of hip function and pain on a scale of 0-100

18 months post intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Kerboul Angle
Time Frame: 18 months post intervention

A radiological assessement measurement of femoral head necrosis by measuring angles from serial MRI scans.

18 months post intervention
Conversion to Total Hip Arthroplasty
Time Frame: 18 months post intervention

A real world indicator of joint preservation showing whether patients were satisfied with the outcome or had to resort to hip replacement surgery.

18 months post intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 25, 2022

Primary Completion (Actual)

February 22, 2025

Study Completion (Actual)

February 22, 2025

Study Registration Dates

First Submitted

November 2, 2026

First Submitted That Met QC Criteria

November 2, 2026

First Posted (Actual)

November 6, 2026

Study Record Updates

Last Update Posted (Actual)

November 6, 2026

Last Update Submitted That Met QC Criteria

November 2, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe